MA49140A - Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques - Google Patents
Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiquesInfo
- Publication number
- MA49140A MA49140A MA049140A MA49140A MA49140A MA 49140 A MA49140 A MA 49140A MA 049140 A MA049140 A MA 049140A MA 49140 A MA49140 A MA 49140A MA 49140 A MA49140 A MA 49140A
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaromatic
- merged
- treatment
- aniline compounds
- dermal disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508997P | 2017-05-19 | 2017-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49140A true MA49140A (fr) | 2020-03-25 |
Family
ID=62620965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049140A MA49140A (fr) | 2017-05-19 | 2018-05-18 | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10988483B2 (fr) |
| EP (1) | EP3624795B1 (fr) |
| JP (1) | JP7237941B2 (fr) |
| KR (1) | KR102659322B1 (fr) |
| CN (1) | CN111093658B (fr) |
| AU (1) | AU2018270292B2 (fr) |
| CA (1) | CA3063535A1 (fr) |
| DK (1) | DK3624795T3 (fr) |
| ES (1) | ES2913213T3 (fr) |
| IL (1) | IL270576B (fr) |
| MA (1) | MA49140A (fr) |
| MX (1) | MX2019013562A (fr) |
| WO (1) | WO2018213807A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111093658B (zh) | 2017-05-19 | 2022-10-14 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 |
| WO2020106307A1 (fr) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| CA2224381A1 (fr) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Production de preparations a liberation prolongee |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (fr) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Formulation a liberation-retard |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| KR20000057693A (ko) | 1996-12-20 | 2000-09-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 지효성 제제의 제조 방법 |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| CN101155577B (zh) | 2005-02-02 | 2015-04-22 | 耐克斯詹尼克斯医药有限公司 | 神经纤维瘤的局部治疗 |
| AU2006261993B2 (en) | 2005-06-22 | 2011-11-17 | Plexxikon, Inc. | Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors |
| GB0601962D0 (en) * | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| KR101475088B1 (ko) * | 2006-08-21 | 2014-12-23 | 제넨테크, 인크. | 아자-벤조티오페닐 화합물 및 사용 방법 |
| AU2007286808B2 (en) * | 2006-08-21 | 2012-12-06 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| EP2089359A2 (fr) | 2006-10-31 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase mapk/erk |
| CL2007003444A1 (es) | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
| US20080312307A1 (en) | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| GB0714384D0 (en) * | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| ES2387707T3 (es) | 2007-12-21 | 2012-09-28 | Genentech, Inc. | Azaindolizinas y procedimientos de uso |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) * | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| EP2240494B1 (fr) | 2008-01-21 | 2016-03-30 | UCB Biopharma SPRL | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| JP2010043019A (ja) * | 2008-08-12 | 2010-02-25 | Taisho Pharmaceutical Co Ltd | ピペリジニルピペラジン化合物 |
| US8324239B2 (en) * | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
| WO2012040636A2 (fr) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase |
| WO2014179785A1 (fr) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Répulsifs améliorés contre les abeilles domestiques et leurs utilisations |
| CN105384754B (zh) | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| EP3624796A1 (fr) | 2017-05-19 | 2020-03-25 | NFlection Therapeutics, Inc. | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau |
| CN111093658B (zh) | 2017-05-19 | 2022-10-14 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 |
-
2018
- 2018-05-18 CN CN201880048242.4A patent/CN111093658B/zh active Active
- 2018-05-18 CA CA3063535A patent/CA3063535A1/fr active Pending
- 2018-05-18 EP EP18731592.4A patent/EP3624795B1/fr active Active
- 2018-05-18 ES ES18731592T patent/ES2913213T3/es active Active
- 2018-05-18 AU AU2018270292A patent/AU2018270292B2/en active Active
- 2018-05-18 DK DK18731592.4T patent/DK3624795T3/da active
- 2018-05-18 JP JP2020514155A patent/JP7237941B2/ja active Active
- 2018-05-18 MX MX2019013562A patent/MX2019013562A/es unknown
- 2018-05-18 KR KR1020197037274A patent/KR102659322B1/ko active IP Right Grant
- 2018-05-18 MA MA049140A patent/MA49140A/fr unknown
- 2018-05-18 WO PCT/US2018/033544 patent/WO2018213807A1/fr active Application Filing
- 2018-05-18 US US16/615,059 patent/US10988483B2/en active Active
-
2019
- 2019-11-11 IL IL270576A patent/IL270576B/en unknown
-
2021
- 2021-04-20 US US17/235,018 patent/US11542271B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200026812A (ko) | 2020-03-11 |
| US20210380601A1 (en) | 2021-12-09 |
| IL270576B (en) | 2022-01-01 |
| CN111093658B (zh) | 2022-10-14 |
| JP2020520994A (ja) | 2020-07-16 |
| US10988483B2 (en) | 2021-04-27 |
| JP7237941B2 (ja) | 2023-03-13 |
| US11542271B2 (en) | 2023-01-03 |
| KR102659322B1 (ko) | 2024-04-22 |
| AU2018270292B2 (en) | 2022-02-10 |
| DK3624795T3 (da) | 2022-05-23 |
| WO2018213807A1 (fr) | 2018-11-22 |
| US20200172550A1 (en) | 2020-06-04 |
| CA3063535A1 (fr) | 2018-11-22 |
| EP3624795A1 (fr) | 2020-03-25 |
| EP3624795B1 (fr) | 2022-04-20 |
| AU2018270292A1 (en) | 2019-12-05 |
| CN111093658A (zh) | 2020-05-01 |
| MX2019013562A (es) | 2020-08-03 |
| ES2913213T3 (es) | 2022-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1034I1 (fr) | Composés aryle, hétéroaryle et hétérocycliques pour le traitement de troubles induits par un complément | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA44737A (fr) | Compositions pour le traitement de troubles liés à l'hyperkératose | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| IL270752B (en) | Pyrrolopyridine-aniline compounds for the treatment of skin disorders | |
| MA46524A (fr) | Composés de biphényl-sulfonamide destinés au traitement de néphropathies | |
| MA50391A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA47212A (fr) | Méthodes de traitement de troubles neurologiques | |
| MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
| MA52778A (fr) | Méthodes de traitement de troubles associés au récepteur s1p1 | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA46099A (fr) | Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides |